However, the analysis of PFS revealed that high expression of HMGB3 was associated with poor survival in patients with the HER2-positive and ER-positive breast cancer subtypes (p<0.001) (Figures 4G, K), but not in those with the TNBC breast cancer subtype (p=0.134) (Figure 4I). Here, HMGB3 is linked to breast cancer.